[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sichuan Enray Pharmaceutical Sciences Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100630754","phase-2-nano-carbon-iron-suspension-injection-combined-with-radiotherapy-for-solid-tumors-phase-ii-clinical-trial-100630754",false,"NCT07491783","Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial","A Multicenter, Open-label Phase II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Intratumoral Injection of Carbon Nanoparticle Iron Suspension (CNSI-Fe) in Combination With Radiotherapy in Patients With Solid Tumors","Inclusion Criteria:\n\n1. Participants voluntarily sign a written Informed Consent Form (ICF), can communicate effectively with the investigator, and are able to comply with study requirements.\n2. Age ≥ 18 years and ≤ 80 years, regardless of gender.\n3. Histologically or cytologically confirmed solid tumors, including soft tissue sarcoma, head and neck squamous cell carcinoma, etc., assessed by the investigator as suitable for standard radiotherapy, including preoperative neoadjuvant radiotherapy (Cohort A1) or definitive radiotherapy for patients unsuitable for surgery (Cohort A2).\n4. ECOG score of 0-1.\n5. Estimated survival ≥ 12 weeks.\n6. Limited oligometastasis (≤ 5 lesions).\n7. According to RECIST 1.1 criteria, participants have at least one radiologically measurable lesion that has not previously received radiotherapy (unless the lesion progressed clearly after radiotherapy).\n8. At least one injectable lesion (e.g., directly injectable or via medical imaging guidance), determined by the investigator to be suitable for repeated intratumoral injection.\n9. Drug-related adverse reactions from prior treatments have recovered to Grade 1 or lower per NCI CTCAE v6.0 at screening (excluding alopecia, Grade 2 or lower peripheral neurotoxicity, or other toxicities judged by the investigator to pose low safety risk).\n10. Left ventricular ejection fraction (LVEF) ≥ 50% assessed by cardiac evaluation.\n11. Within 7 days prior to first dosing, adequate hematologic and end organ function per laboratory tests meeting the following criteria:\n\n    1. Hematology No use of granulocyte colony-stimulating factor (G-CSF) or similar treatments within 14 days prior to hematology lab testing, and absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; No platelet transfusion or use of interleukin-11 (IL-11), recombinant human thrombopoietin injection, or similar treatments within 7 days prior to hematology lab testing, and platelet count (PLT) ≥ 90×10⁹\u002FL; No blood transfusion or use of erythropoietin within 14 days prior to hematology lab testing, and hemoglobin (Hb) ≥ 90 g\u002FL;\n    2. Coagulation function International normalized ratio (INR) ≤ 1.5×upper limit of normal (ULN), activated partial thromboplastin time (APTT) ≤ 1.5×ULN; Note: Participants receiving anticoagulant therapy with injectable lesions in the skin and\u002For subcutaneous tissue may have prolonged INR and APTT as direct pressure can control excessive bleeding, determined by the investigator; for participants receiving anticoagulant therapy and undergoing deep lesion injection, discontinuation of anticoagulant therapy for at least 1 week prior to injection is recommended, determined by the investigator.\n    3. Renal function Serum creatinine (Cr) ≤ 1.5×ULN, or calculated creatinine clearance ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula (creatinine clearance calculation is performed only when baseline Cr \\> 1.5×ULN);\n    4. Hepatic function total bilirubin (TBIL) ≤ 1.5×ULN, or ≤ 3×ULN for participants with Gilbert's syndrome or hepatic metastases; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations ≤ 3×ULN, or ≤ 5×ULN if elevated due to hepatic metastases as determined by the investigator; Serum albumin ≥ 2.8 g\u002FdL.\n12. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dosing of study drug, commit to practicing effective contraception or abstinence during the study drug treatment period and for 6 months after completion of study drug treatment, and must not be lactating.\n\nMale participants must commit to practicing effective contraception or abstinence during the study drug treatment period and for 6 months after completion of study drug treatment. Additionally, male participants must agree not to donate sperm during this period.\n\nExclusion Criteria:\n\n1. History or current diagnosis of iron metabolism disorders (excluding participants with iron deficiency anemia), such as thalassemia, favism (red blood cell glucose-6-phosphate dehydrogenase deficiency), etc.\n2. Evidence of hollow viscus perforation at the injection site either previously or currently.\n3. Local skin ulceration, erythema, necrosis, hemorrhage or other conditions affecting investigational drug administration at the injection site either previously or currently.\n4. Known history or current coagulation defects causing increased bleeding risk, or any known hemorrhagic disorders.\n5. Received systemic chemotherapy, small molecule targeted therapy or hormonal anti-tumor treatment within 2 weeks prior to first administration of investigational medication; received macromolecular biologics anti-tumor treatment within 4 weeks prior to first administration of investigational medication; received prior radiotherapy within 14 days prior to first administration of investigational medication \\[central nervous system (CNS) radiotherapy excluded, requiring ≥28 days washout period\\]; received traditional Chinese medicine with anti-tumor indication within 14 days prior to first administration of investigational medication.\n6. Undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to first administration of investigational medication, or other surgical conditions deemed unsuitable for enrollment by the investigator (fine needle aspiration at tumor site is allowed).\n7. Contraindications for concomitant therapy: infection, active inflammation, severe skin lesions or other conditions deemed unsuitable for radiotherapy at the intended irradiation sites;\n8. Untreated or active brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence indicating uncontrolled central nervous system metastases (excluding cases with stable symptoms after treatment, radiological evidence of stability for at least 4 weeks prior to first administration, absence of cerebral edema evidence, and no requirement for corticosteroid treatment).\n9. Uncontrolled or poorly controlled hypertension (e.g., systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg).\n10. Uncontrolled tumor-related pain.\n11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once\u002Fmonth or more frequently).\n12. Received live virus vaccination within 4 weeks prior to first administration of investigational medication.\n13. History of immunodeficiency disease, including human immunodeficiency virus (HIV) positive status or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.\n14. Active hepatitis B virus (HBV) infection \\[HBV DNA quantitative \\>500 IU\u002FmL\\], or hepatitis C virus (HCV) infection \\[HCV antibody positive with HCV ribonucleic acid (RNA) polymerase chain reaction (PCR) exceeding upper limit of normal\\].\n15. Severe chronic or active infection (including tuberculosis infection) requiring systemic antibacterial, antifungal or antiviral treatment prior to first administration of investigational medication, viral hepatitis participants receiving antiviral treatment are allowed.\n16. Other active malignancies outside the study tumor type occurred within 5 years prior to first administration of investigational medication, excluding non-melanoma skin cancers treated with curative intent, localized prostate cancer, ductal carcinoma in situ, stage I endometrial cancer, cervical carcinoma in situ, differentiated thyroid cancer or breast carcinoma in situ.\n17. History of severe heart failure, stroke or transient ischemic attack within 6 months prior to first administration of investigational medication. History of ventricular tachycardia or torsade de pointes arrhythmia within 14 days prior to first administration, and any clinically significant abnormalities in rhythm, conduction or morphology on resting ECG. Diagnosed with clinically significant cardiac diseases including acute myocardial infarction, III or IV class congestive heart failure (New York Heart Association classification, see Appendix 3), unstable angina pectoris or arrhythmias requiring treatment within 6 months prior to first administration. Note: Participants with arrhythmia receiving anti-arrhythmic medication with controlled heart rate rhythm as shown on screening ECG may be enrolled.\n18. Participated in other interventional clinical studies within 3 weeks prior to first administration of investigational medication (calculated from the day after last administration in previous study, excluding cases without exposure to investigational drugs or medical devices).\n19. Diagnosed with active psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, etc.).\n20. Participants with known allergy or intolerance to active ingredients or excipients in the investigational medication.\n21. Other conditions deemed unsuitable for enrollment by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},52,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study Primary Objective: To evaluate the efficacy of CNSI-Fe intra-tumoral injection combined with radiotherapy in patients with solid tumors.\n\nStudy Secondary Objectives:\n\n1. To evaluate the efficacy of CNSI-Fe intra-tumoral injection combined with radiotherapy at both injected and non-injected lesions;\n2. To evaluate the safety and tolerability of CNSI-Fe intra-tumoral injection combined with radiotherapy in patients with solid tumors;\n3. To evaluate the pharmacokinetic (PK) characteristics of CNSI-Fe intra-tumoral injection combined with radiotherapy in patients with solid tumors.\n\nStudy Population: Patients with histologically or cytologically confirmed solid tumors including soft tissue sarcoma, head and neck squamous cell carcinoma, etc., who are assessed by the investigator as suitable for standard radiotherapy including preoperative neoadjuvant radiotherapy (Cohort A1) or definitive radiotherapy for patients not suitable for surgery (Cohort A2)\n\nStudy Drug Administration Schedule: Single administration, 2 weeks per administration cycle, total 1-4 cycles\n\nStudy Primary Endpoint: Objective Response Rate (ORR) assessed according to RECIST 1.1 criteria\n\nStudy Key Secondary Endpoints:\n\n1. Patients with unresectable locally advanced or advanced solid tumors: Local Control Rate (LCR), Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DOR), Time to Progression (TTP), Time to Response (TTR), and Overall Survival (OS);\n2. Patients receiving preoperative neoadjuvant therapy: Major Pathological Response (MPR), Disease-Free Survival (DFS), Disease Control Rate (DCR);",[27,28],"HNSCC","Soft Tissue Cancer","NOT_YET_RECRUITING","2026-03-19",{"date":32,"type":33},"2026-03-24","ACTUAL",{"date":35,"type":21},"2026-03-27",{"date":37,"type":21},"2028-12-30",{"name":39,"class":40},"Sichuan Enray Pharmaceutical Sciences Company","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100626257","phase-1-carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor-100626257","NCT07433283","Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor","A Phase Ib\u002FIIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of Intratumoral Injection of Carbon Nanoparticle-Loaded Iron Suspension Injection [CNSI-Fe(II)] With Multiple Administrations in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\nPatients must meet all of the following criteria to be eligible:\n\n1. Understand and voluntarily sign the written informed consent form (ICF), be willing and able to comply with all trial requirements;\n2. Male or female aged 18\\~80 years old (including cut-off value) at the time of signing the ICF;\n3. Stage Ib: patients with advanced solid tumors confirmed by histology or cytology, and the current standard therapy is ineffective (disease progression after treatment or treatment is not tolerated) or there is no effective standard treatment, such as soft tissue sarcoma, refractory thyroid cancer, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, cervical cancer, lung cancer, head and neck cancer, liver cancer, bile duct cancer, kidney cancer, prostate cancer, vulvar cancer, etc.; Note: Subjects with advanced solid tumors whose disease progresses due to no standard therapy for any reason, or advanced solid tumors whose disease has progressed after receiving the first course of standard therapy for tumor types that are not sensitive to existing standard therapies (e.g., pancreatic cancer, undifferentiated thyroid cancer, sarcoma, etc.) can be included.\n4. At least one measurable lesion according to RESICT v1.1 and the lesion has not previously undergone radiotherapy (unless the lesion has clearly progressed after radiotherapy) and has not undergone a tissue biopsy within 7 days prior to screening;\n5. Have injectable lesions (such as direct injection or assisted injection by medical imaging instruments), which are judged by the investigator to be suitable for repeated intratumoral injection;\n6. The ECOG score within 7 days before the first dose is 0\\~1 points;\n7. Expected survival ≥ 3 months;\n8. Adverse drug reactions (ADRs) caused by prior therapy have recovered to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria grade 1 and below before screening (alopecia, grade 2 or below peripheral neurotoxicity, etc., except for toxicities judged by the investigator to be of low safety risk);\n9. Left ventricular ejection fraction (LVEF) ≥50%;\n10. Within 7 days prior to the first dose, adequate hematologic and end-organ function with laboratory tests meeting the following criteria:\n\n    haematology No treatment with granulocyte colony-stimulating factor (G-CSF) within 14 days prior to hematology laboratory tests, and absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; Have not been treated with platelet transfusion or interleukin-11 (IL-11) or recombinant human thrombopoietin injection before hematological laboratory examination, and the platelet count (PLT) ≥ 90×109\u002FL; No blood transfusion or erythropoietin within 14 days prior to hematology laboratory tests, and hemoglobin (Hb) ≥ 90 g\u002FL; Kidney function Serum creatinine (Cr) ≤ 1.5× upper limit of normal (ULN) or 50 mL\u002Fmin (Cr only) calculated using the Cockcroft-Gault formula (Cr) 50 mL\u002Fmin (Cr ≥\\> only). 1.5 Calculate Ccr when ×ULN); Liver function TBIL ≤ 1.5× ULN (3.0 ≤× ULN for subjects with Gilbert's syndrome or liver metastases);\n\n    AST, ALT, and ALP≤3×ULN, and subjects with confirmed liver metastases or bone metastases must meet the following conditions:\n\n    Subjects with confirmed liver metastases: AST and ALT≤5×ULN; Subjects with confirmed bone metastases: ALP≤5×ULN; serum albumin≥ 2.8 g\u002FdL; Coagulation function International normalized ratio (INR) or prothrombin time (PT) and aPTT ≤1.5×ULN; Note: Subjects receiving anticoagulant medication are allowed to prolong their INR, PT and aPTT if the injected lesion is in the skin and\u002For subcutaneous, because excessive bleeding can be controlled by applying direct pressure, at the discretion of the investigator; Subjects receiving anticoagulant therapy are advised to discontinue anticoagulant medication for at least 1 week before deep lesion injection, at the discretion of the investigator.\n11. Female subjects of childbearing potential (WOCBP) who must have a negative serum pregnancy test result within 7 days prior to the first dose of study drug and a commitment to adequate and effective contraception or abstinence during treatment with study drug and for 6 months after the end of study drug treatment. In addition, female subjects must be non-lactating.\n\n    Note: WOCBP is defined as non-postmenopausal women who have experienced menarche but have not yet undergone sterilization surgery (hysterectomy or bilateral salpingectomy). Postmenopausal is defined as meeting any of the following conditions: (1) prior bilateral oophorectomy; (2) Age≥ 60 years old; (3) Age \\\u003C 60 years and have been out of menstruation for 12 months or more without chemotherapy and taking tamoxifen, toremifene and ovarian function suppression therapy; (4) If taking tamoxifen or toremiaphene and \\\u003C age 60 years, FSH and plasma estradiol levels must be in the postmenopausal range.\n\n    Hormone replacement therapy (HRT) may artificially suppress FSH levels in women and may require a washout period to return to physiological FSH levels. The duration of the washout period is one of the effects of the HRT type. The following washout period duration is recommended as a guideline, and the investigator should judge the results of the serum FSH level on his own.\n\n    vaginal hormonal preparations (drug rings, creams, gels) for at least 1 week; transdermal preparation for at least 4 weeks; Oral preparation for at least 8 weeks; Other parenteral preparations may require a washout period of up to 6 months. If the serum FSH level \\> 40 mIU\u002FmL during the washout period, a postmenopausal woman may be considered.\n12. Male subjects commit to adequate and effective contraception or abstinence during study drug treatment and for 6 months after the end of study drug treatment. In addition, male subjects must agree not to donate sperm during this period.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria cannot participate in this clinical study:\n\n1. Previous or current diseases with abnormal iron metabolism (except for subjects with iron deficiency anemia), such as thalassemia, fava bean disease (erythrocyte glucose-6-phosphate dehydrogenase deficiency), etc.;\n2. Signs of perforation of hollow viscera at the previous or current injection site;\n3. Previous or current injection site with local skin breakdown, redness, swelling, necrosis, bleeding, etc., which affects the injection of study drugs;\n4. Systemic chemotherapy, targeted therapy, anti-tumor biologic therapy, or immunotherapy within 3 weeks prior to the first dose of study drug; Prior radiotherapy within 14 days prior to the first dose of study drug (with the exception of central nervous system \\[CNS\\] radiotherapy, which requires a washout period of ≥ 28 days); Received traditional Chinese medicine with anti-tumor indications within 2 weeks before the first dose of the study drug;\n5. Major surgery within 4 weeks prior to the first dose of study drug or unhealed wounds, ulcers, or fractures (except for minor surgeries performed within 1 week and full recovery);\n6. Untreated or with active brain metastases, spinal cord compression, carcinomatous meningitis, or other evidence that the subject's brain or spinal cord metastases have not been controlled (except for those who have been treated and have stable symptoms, have been stable for at least 4 weeks before the first dose on imaging tests, and have no evidence of cerebral edema, and do not require glucocorticoid therapy);\n7. Uncontrolled or poorly controlled hypertension (e.g., systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg);\n8. Uncontrolled tumor-related pain;\n9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once\u002Fmonth or more often);\n10. Active malignancy within 5 years prior to the first dose of study treatment, with the exception of non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ or stage I uterine cancer, cervical carcinoma in situ, or carcinoma in situ of the breast that has received curative therapy;\n11. Vaccination with a live virus vaccine within 4 weeks prior to the first dose of study treatment; Note: Seasonal influenza vaccines for injection are usually inactivated influenza vaccines and are permitted; However, intranasal influenza vaccine is a live attenuated vaccine and is not allowed.\n12. Those with a history of immunodeficiency, including human immunodeficiency virus (HIV) positive or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;\n13. Active hepatitis B virus (HBV) infection (HBV DNA quantification \\>500 IU\u002FmL), hepatitis C virus (HCV) infection (HCV antibody positive and polymerase chain reaction \\[PCR\\] of HCV ribonucleic acid \\[RNA\\] exceeds ULN), positive anti-human immunodeficiency virus antibody (Anti-HIV). Those who meet any of the above items;\n14. Severe chronic or active infection (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy prior to the start of study treatment; Note: Subjects with viral hepatitis are allowed to receive antiviral therapy.\n15. History of severe cardiac insufficiency, stroke, or transient ischemic attack (TIA) within 6 months prior to enrollment. History of ventricular tachycardia or torsade de pointes. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG. Has clinically significant cardiac disease, including acute myocardial infarction, Class III or IV congestive heart failure (New York Heart Association classification, see Appendix 5 for details), unstable angina, or cardiac arrhythmia requiring treatment that occurred within 6 months prior to the first dose of study treatment. Note: Subjects with arrhythmias who are receiving anti-arrhythmic drugs and have a controlled heart rate rhythm on screening ECG can be enrolled.\n16. Have an active psychiatric disorder (schizophrenia, major depressive disorder, bipolar disorder, etc.);\n17. Subjects who are known to be allergic or intolerant to the active ingredient or excipient of the study drug;\n18. Have participated in other interventional clinical studies within 3 weeks prior to the start of study treatment administration (calculated from the first day after the last dose of the previous study, except for those who have not used interventional drugs or investigational medical devices);\n19. Other conditions judged by the investigator to be unsuitable for participation in this trial",{"count":50,"type":21},54,[52,24],"PHASE1","Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway. CNSI-Fe intratumoral injection has the following three effects: 1. Nanocarbon can increase the content of hydrogen peroxide in tumor cells and tumor microenvironment, and is a reactive oxygen species that catalyzes hydrogen peroxide through the Fenton reaction of iron ions to produce \"ferroptosis\", which complements each other; 2. The adsorption of Fe2+ by nanocarbon can help Fe2+ better enter the cell, thereby exerting anti-tumor effects; 3. The lesion localization and lymphatic tracing functions of nanocarbon are retained. The combination of the regulatory mechanism of ferroptosis and the characteristics of nanocarbon particles has increased the advantages of new nanopharmaceuticals in cancer prevention and treatment.\n\nAt present, CNSI-Fe has carried out a first-in-human phase I clinical trial of dose escalation in subjects with advanced solid tumors in China, and has conducted safety and efficacy exploration in four dose groups, including: 30 mg, 60 mg, 90 mg, and 120 mg, and the overall safety and tolerability of the 16 subjects enrolled have been good, no obvious liver and kidney impairment and hematologic toxicity have been observed, and only one subject in the 90 mg dose group has a dose-limiting toxicity (DLT) event; Partial response (PR) was observed in 1 subject (30 mg group), complete tumor response (CR) was observed in 1 subject (60 mg group), and stable tumor (SD) was observed in 11 subjects (including 1 in the 30 mg group, 2 in the 60 mg group, 5 in the 90 mg group, and 3 in the 120 mg group), and the disease control rate (DCR) of the trial treatment was 87%. This Phase I clinical study is planned to continue dose exploration at 150 mg or higher.\n\nTherefore, based on the results of the Phase I clinical trial obtained, it is planned to conduct this Phase Ib\u002FIIa clinical study in subjects with advanced solid tumors in China to further evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and preliminary efficacy of CNSI-Fe intratumoral injection and multiple administration, so as to provide a basis for clinical development in the later stage.",[55,56,57,58,59,60,61],"Tumor, Solid","Lung Cancer","Pancreas Cancer","Thyroid Cancer","Colorectal Cancer","Cervical Cancer","Vulva Cancer",[63,64,65],"Intratumoral Injection","Carbon Nanoparticle-Loaded Iron","Advanced Solid Tumor","RECRUITING","2026-02-24",{"date":69,"type":33},"2026-02-25",{"date":71,"type":33},"2024-11-12",{"date":73,"type":21},"2026-12-31",{"name":39,"class":40},9,""]